IDH1 MUTATIONS AS A IMMUNOTHERAPEUTIC TARGET FOR BRAIN TUMORS

BACKGROUND: Immunotherapy promises an exquisitely precise therapeutic approach, and substantial evidence suggests that activated T cells can eradicate large tumors, even within the “immunologically privileged” brain. EGFRvIII and isocitrate dehydrogenase 1 (IDH1) mutations are two of the only consis...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Archer, Gary E., Reap, Elizabeth, Norberg, Pam, Cui, Xiuyu, Schmittling, Robert, Herndon, James, Chandramohan, Vidya, Riccione, Katherine, Kuan, Chien-Tsun, Yan, Hai, Bigner, Darell D., Sampson, John H.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2014
Matèries:
abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4144614/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou208.65
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars